Compugen to Present at the BIO CEO & Investor Conference 2012
06 Febrero 2012 - 6:00AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) announced today that Dr. Anat
Cohen-Dayag, Compugen's President and CEO, is scheduled to present
at the upcoming BIO CEO & Investor Conference 2012 at 10:00 AM
(Eastern Time) on Monday, February 13, 2012 at the Waldorf Astoria
Hotel in New York City.
A live Webcast of the presentation will be available at
http://www.veracast.com/webcasts/bio/ceoinvestor2012/12105479.cfm
and on the Compugen Website. A replay will be available one hour
after the presentation ends and will be accessible for three months
following the presentation.
About Compugen
Compugen is a leading therapeutic product discovery company
focused on therapeutic proteins and monoclonal antibodies to
address important unmet needs in the fields of immunology and
oncology, either for Compugen or its partners. Unlike traditional
high throughput trial and error experimental based drug candidate
discovery, Compugen's discovery efforts are based on systematic and
continuously improving in silico (by computer) product candidate
prediction and selection followed by experimental validation, with
selected product candidates being advanced in its Pipeline Program
to the pre-IND stage. Compugen's in silico predictive models
utilize a broad and continuously growing infrastructure of
proprietary scientific understandings and predictive platforms,
algorithms, machine learning systems and other computational
biology capabilities. The Company's business model primarily
involves collaborations covering the further development and
commercialization of Compugen-discovered product candidates and
various forms of research and discovery agreements, in both cases
providing Compugen with potential milestone payments and royalties
on product sales or other forms of revenue sharing. In 2002,
Compugen established an affiliate, Evogene Ltd. (www.evogene.com)
(TASE: EVGN.TA), to utilize certain of the Company's in silico
predictive discovery capabilities in agricultural biotechnology.
For additional information, please visit Compugen's corporate
website at www.cgen.com.
This press release may contain “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements include words such as “may”, “expects”,
“anticipates”, “believes”, and “intends”, and describe opinions
about future events. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Some of
these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks
relating to the development of new products; and the ability to
implement technological improvements. These and other factors are
discussed in the "Risk Factors" section of Compugen’s Annual Report
on Form 20-F for the year ended December 31, 2010 as filed with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen’s views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024